Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | PTGER2 | P43116 | 7/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | USP8 | P40818 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3459567 | 0.88 | PTGER2 (0.35) | F2PTGER2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL6516015 | 0.88 | PTGER2 (0.31) | PTGER2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL533748 | 0.88 | SLC1A3 (0.32) | PTGER2SLC1A3SLC1A2SLC1A1ADAM17 | |
| SCHEMBL12983630 | 0.84 | PTGER2 (0.42) | PTGER2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL534421 | 0.83 | SLC1A3 (0.31) | SLC1A3SLC1A2SLC1A1ADAM17 | |
| SCHEMBL12982087 | 0.82 | DAGLA (0.33) | F2PTGER2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3458631 | 0.81 | PTGER2 (0.41) | PTGER2 | |
| SCHEMBL6516006 | 0.80 | PTGER2 (0.32) | PTGER2SLC1A3SLC1A2SLC1A1ADAM17 | |
| SCHEMBL3458643 | 0.80 | PTGER2 (0.32) | PTGER2 | |
| SCHEMBL534420 | 0.78 | ADAM17 (0.37) | SLC1A3SLC1A2SLC1A1ADAM17USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | disclosed |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2264009-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | Ube Industries, Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | F2 406/4885PTGER2 1/4885SLC1A3 450/4885 |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | F2 576/4885PTGER2 1/4885SLC1A3 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.